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ABSTRACT
Miltefosine is an ether lipid that was initially developed for cancer
treatment in the early 1980s. Miltefosine largely failed de-
velopment for oncology, although it was approved for the topical
treatment of breast cancer metastasis. It was subsequently
discovered that miltefosine is a highly effective treatment of
visceral Leishmaniasis, a parasitic disease that affects millions
worldwide and causes an estimated 30,000 fatalities each year.
Oral treatment with miltefosine is generally well tolerated and
has relatively few adverse effects. The exact mechanism of
action of miltefosine treatment is still under investigation. Its
close resemblance to phospholipids allows it to be quickly taken
up by cell membranes and affect related processes, such as lipid
metabolism and signaling through lipid rafts. These processes
play an important role in the immune response and it comes as
no surprise that miltefosine has been successfully tested for the
treatment of a number of immune-mediated diseases in preclinical
models of disease. Drug repurposing of miltefosine for immune-
mediated diseases may provide an opportunity to expand the
limited number of drugs that are currently available for therapeutic
use.
Introduction
Miltefosine, or hexadecylphosphocholine, was developed in
the early 1980s as a potential cytostatic drug. Miltefosine
largely failed development for oncology and is now best known
as an oral treatment of visceral Leishmaniasis, a lethal disease
that results from infection with the Leishmania parasite. Dis-
covery of miltefosine’s potential as an antiparasitic drug in
recent years has renewed scientific interest in the drug and
its mechanism of action. Development of new drugs is a costly
and time-consuming process with a high risk of failure at
multiple steps along the road of preclinical and clinical develop-
ment. This makes repurposing of existing drugs with estab-
lished side effects for novel indications an attractive alternative
to classic drug development. Miltefosine has been exten-
sively investigated in large clinical trials and appears to be
relatively safe with limited and reversible side effects. This
review focuses on the potential to repurpose miltefosine as an
anti-inflammatory drug for immune-mediated diseases. To note,
this review does not cover perifosine, an alkyl-phospholipid
developed to improve oral tolerability. Assuming that the
mechanism of action of perifosine is similar to that ofmiltefosine,
perifosine could be an alternative candidate for repurposing.
However, the number of studies that address perifosine for
applications other than cancer treatment is very limited.
Miltefosine (hexadecylphosphocholine) is an alkyl-phospholipid
or ether lipid with structural resemblance to lysophospha-
tidylcholine (LPC), a type of phospholipid that is present in
the cell membrane and comprises approximately 3% of the
cellular membrane. LPCs have a very short half-life because
they are quickly metabolized by phospholipases and acyl-
transferases. An acyl group is replaced by an alkyl group in
the LPC analogs miltefosine, perifosine, and edelfosine (Fig. 1),
which makes these compounds metabolically stable (Eibl and
Unger, 1990). The first stable LPC analog was synthesized
with an interest in enhancing macrophage-mediated antitu-
mor immunity (Munder et al., 1976) because LPCs were found
to increase the phagocytic capacity of peritoneal macrophagesdx.doi.org/10.1124/jpet.113.212654.
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(Burdzy et al., 1964). It was subsequently discovered that some
of these alkyl-phospholipids possessed direct cytostatic proper-
ties, shifting the interest away from their immunomodulatory
properties. Because the ability to inhibit cell growth appeared to
be related to structural properties, researchers attempted to
create the most minimal structure required. This resulted in
a new group of molecules (alkylphosphocholines) and the
discovery of miltefosine and edelfosine (Munder et al., 1979).
Screening of miltefosine in cancer cell lines suggested that
miltefosine possesses potent antineoplastic properties. Milte-
fosine inhibited cell growth in various leukemic cell lines
(Unger et al., 1989) and reduced tumor weight and size in
dimethylbenzanthracene-induced mammary carcinomas and
transplanted mammary tumors in rats in vivo (Scherf et al.,
1987). However, miltefosine appeared to only be effective
against some cell types, because no effect was observed in
a variety of other cancer cell lines, such as rat DS-carcinosarcoma,
AH 13s sarcoma and L5222 leukemia cells, mouse L1210 and
P388 lymphocytic leukemia cells, Lewis lung carcinoma cells,
and B16 melanoma cells. The reason for this differential
sensitivity of cancer cell lines to miltefosine has not been
established,
Development of Miltefosine for Oncology
Because intravenous administration of miltefosine is hemo-
lytic, clinical applications have been limited to topical and
oral treatments. A phase II dose-finding study in cancer
patients confirmed previous phase I data showing that the
major dose-limiting toxicity effects were nausea and vomit-
ing and suggested a maximum dose of 150 mg/d split into
three doses (Verweij et al., 1992). Oral treatment was sub-
sequently tested in a number of oncological trials, including
a phase II study for treatment of soft tissue sarcomas (Verweij
et al., 1993b), a phase II study in advanced nonsmall cell lung
cancer (Berdel et al., 1992), a phase II study in advanced
colorectal cancer (Planting et al., 1993), a phase II study in
advanced breast cancer (Unger et al., 1993), and a phase II
study for squamous cell head and neck cancer (Verweij et al.,
Fig. 1. Chemical structure of lysophosphatidylcholine and synthetic analogs. Lysophosphatidylcholine (also known as lysolecithin) is a natural
occurring phospholipid present in cellular membranes. The lipid is easily metabolized, a problem that was solved in synthetic analogs by replacing the
acyl group with a more resistant alkyl group. This change causes the ester, linking oxygen to the acyl group, to be changed into an ether.
190 Verhaar et al.
1993a). None of these phase II clinical trials showed a sign
that miltefosine treatment might affect disease progression.
The only trials that showed an effect of miltefosine were
studies in which miltefosine was topically applied. A 6%
topical miltefosine solution was successfully applied in a
phase II study for cutaneous T-cell lymphomas (Dumontet
et al., 2006) and in a multicenter, randomized, placebo-
controlled phase III study for the treatment of skin metastasis
of mammary carcinoma (Leonard et al., 2001). Reasonable
efficacy was observed in the latter trial, with 2 of 24 patients
achieving a complete response of the skin lesions (0 of 27 for
placebo) and 6 of 24 showing a partial response (1 of 27 for
placebo).
Leishmaniasis
Leishmaniasis is a disease caused by infection of macro-
phages by a protozoan parasite belonging to the genus Leish-
mania. The parasites are transferred by a type of sandfly that
only lives in (sub)tropical regions, restricting the disease to
those areas. The infection can lead to cutaneous, mucocuta-
neous, or visceral disease (also called kala-azar). Visceral
Leishmaniasis is characterized by bouts of fever, weight loss,
hepatosplenomegaly, and anemia, and is lethal if left un-
treated (Chappuis et al., 2007). Unfortunately, the incidence
of visceral Leishmaniasis is estimated at 200,000–400,000 per
year worldwide, with approximately 20,000–30,000 fatalities
per year (Alvar et al., 2012). In 95% of cases, the disease can
be quite effectively treated with intravenous injections of am-
photericin B or pentavalent antimonial drugs (e.g., sodium
stibogluconate and meglumine antimoniate). These drugs are
inexpensive but treatment requires a trained physician to per-
form the injection and patients often succumb before reaching
a doctor. More importantly, the number of patients showing
resistance to treatment is increasing and patients with visceral
Leishmaniasis in combination with AIDS are generally re-
fractory to treatment with pentavalent antimonial drugs.
The development of an in vitro model for infecting
primary mouse peritoneal macrophages with Leishmania
donovani in the 1980s allowed screening of large libraries
of compounds for possible new treatments (Croft, 1986).
These screenings resulted in the discovery of alkyl-phospholipids
as possible candidates (Croft et al., 1987). Kuhlencord et al.
(1992) first showed that Leishmaniasis can indeed be treated
with miltefosine in vivo. Mice infected with L. donovani and
Leishmania infantum were treated orally with miltefosine
and compared with standard treatment using sodium
stibogluconate. Parasitic levels in spleen and liver after
4 weeks of treatment in mice showed that miltefosine was
more potent in both suppressing and killing Leishmania
parasites than sodium stibogluconate (Kuhlencord et al.,
1992).
The use of miltefosine as an oral treatment of visceral
Leishmaniasis was tested in numerous trials (Sundar et al.,
1998, 2002, 2011; Jha et al., 1999). Different treatment
strategies were used, but patients with visceral Leishmani-
asis generally received 50 or 100 mg/d miltefosine for 28 days.
On average, treatment was well tolerated and adverse effects
were limited to gastrointestinal side effects such as vomiting
and diarrhea. Treatment withmiltefosine resulted in a 90–100%
cure rate.
Immunomodulatory Effects of Miltefosine
The development of alkyl-phospholipids initially started
with the aim to create an immunomodulator that would
increase antitumor phagocytic capacity of tumor-associated
macrophages. Miltefosine exhibits immunomodulatory prop-
erties that are similar to the originally developed compounds.
Stimulatory Effects on the Innate Immune
Response
There are a number of reports suggesting that miltefosine
may stimulate multiple aspects of monocyte- and macrophage-
mediated immunity. Such effects may explain the potent
clearance of Leishmania parasites that have their niche inside
macrophages. For example, Balb/c mouse monocytes and
macrophages treated with miltefosine showed a more potent
response to LPS, with enhanced secretion of tumor necrosis
factor-a (TNF-a) and release of nitric oxide (NO) (Eue et al.,
1995; Zeisig et al., 1995; Ghosh et al., 2013). In a similar
experiment with macrophages isolated from C57BL/6 mice,
there was no increase in NO release, but miltefosine did in-
crease their phagocytic capacity. Not only did sensitized macro-
phages phagocytize more Saccharomyces cerevisiae after
miltefosine treatment, but miltefosine also increased the
number of macrophages that participated in the process (Ponte
et al., 2012).
One report investigated the effect of miltefosine on
circulating monocytes and cytokine levels in patients suffer-
ing from cutaneous Leishmaniasis (Mukhopadhyay et al.,
2011). The percentage of CD141 monocytes decreased in 12
patients that completed 4 months of miltefosine treatment
(100 mg/d), whereas CD161 monocytes increased. This shift
indicated that miltefosine treatment may have triggered
maturation of the monocyte population toward a more
proinflammatory phenotype. Levels of monocyte-associated
proinflammatory cytokines, such as TNF-a, interleukin (IL)-6,
IL-1b, and IL-8, were significantly increased compared with
these levels at the time of disease presentation. Of course, it
cannot be excluded in this study that some of these effects
were indirect and a systemic response to the eradication of the
Leishmania parasites.
Tissue biopsies were taken from the lesional area in a case
study of one patient suffering from cutaneous Leishmaniasis
treated with miltefosine. Quantitative analysis of mRNA ex-
pression showed a significant decrease of TNF-a, IL-10, and
transforming growth factor-b levels, whereas comparisons
before and after treatment showed that interferon-g and
CD40 were significantly increased (Ansari et al., 2008). CD40
is a costimulatory molecule found on antigen-presenting cells
that helps to stimulate T helper (Th) cells, which, in turn,
produce interferon-g–stimulating macrophages. Again, this
case study comprised a single patient; therefore, it is difficult
to judge whether the changes in expression are the direct
result of the miltefosine treatment or alternatively result from
the eradication of parasite-laden macrophages.
The initial development of alkyl-phospholipids as com-
pounds that stimulate macrophage phagocytosis, the potent
parasite clearance by Leishmania-infected macrophages
together with some of the experiments above suggest that
treatmentwithmiltefosine potentiatesmonocyte andmacrophage-
mediated innate immunity.
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Inhibitory Effects on the Adaptive Immune
Response
Because miltefosine potently inhibits T-cell activation,
miltefosine and other alkyl-phospholipids may have a poten-
tial role in immune-mediated diseases (Bäumer et al., 2010;
Verhaar et al., 2013). This effect was verified in animal
models in which inflammation was successfully reduced using
miltefosine. We investigated the effect of miltefosine in
a CD4CD45RBhigh transfer mouse model of inflammatory
bowel disease (IBD). In this model, SCID mice, which lack
T and B cells, are transplanted with CD45RBhigh T cells
resulting in chronic inflammation of the gut that develops
over the course of several weeks. Miltefosine, given twice
weekly, greatly reduced colonic inflammation in this model.
Miltefosine improved clinical parameters such as weight loss,
significantly improved the pathology score, and reduced the
expression of proinflammatory cytokines il-6, tnf-a, and ifn-g
to levels that were no longer significantly different from
control mice without colitis (Verhaar et al., 2013). These
findings may make miltefosine an attractive candidate for the
treatment of IBD. Although the cause of IBD remains unclear,
there are many indications that suggest that a reduced function
of the innate immune system predisposes to an excessive
response of the adaptive immune response to intestinal micro-
biota (Marks et al., 2006; Hayee et al., 2010; Uhlig, 2013). Given
the results discussed above, miltefosine may have a dual
therapeutic effect in IBD by both stimulating macrophage-
mediated innate immunity and reducing excessive activation
of T cell–mediated adaptive immunity.
Bäumer et al. (2010) investigated miltefosine treatment in
a number of animal models, addressing its effect on Th1- or
Th2-related inflammatory responses and feasibility for use in
atopic dermatitis. Themodels used ear thickness as ameasure
of inflammation. In an ovalbumin-induced delayed-type hyper-
sensitivity model, miltefosine was significantly reduced ear
swelling. Likewise, in the more Th2-orientated mouse model of
toluene diisocyanate–induced hypersensitivity, treatment with
miltefosine significantly reduced ear swelling and proinflamma-
tory cytokine expression, both when administered systemically
as well as topically (Bäumer et al., 2010).
Topical application of a 6% miltefosine solution was com-
pared with 1% hydrocortisone in a small clinical trial of 16
patients (Dölle et al., 2010). Patients with at least two different
target lesions were treated topically with one drug on each
lesion for 3 weeks. Both treatments effectively reduced the
severity of the disease and reduced the number of infiltrating
lymphocytes in the lesions. Patient follow-up revealed a more
sustained effect ofmiltefosine treatment. Interestingly, a closer
examination revealed a local increase in the number of FoxP31
regulatory T cells in the miltefosine-treated lesions, whereas
hydrocortisone reduced the number of FoxP31 cells. An impor-
tant potential advantage of miltefosine over hydrocortisone
was that, in contrast with hydrocortisone, miltefosine did not
affect the proliferation of cells in the basal layer of the epidermis.
Indeed, in contrast with hydrocortisone, no reduction in epider-
mal thickness was observed with miltefosine.
Miltefosine and Allergic Disease
A potential role for miltefosine in allergic disease was
suggested when it was shown that miltefosine can reduce
histamine release from rat primary mast cells (Grosman 1990).
Mast cells contain large granules with inflammatory mediators
such as cytokines, proteases, histamine, serotonin, and eicosa-
noids. Mast cells release their granules in response to activation
by pattern recognition receptors or cross-linking of the IgE
receptor. Degranulation causes redness of the skin as well as
swelling and itching.
Miltefosine was also shown to inhibit histamine release in
human mast cells (Weller et al., 2009; Batista et al., 2010,
2011). Ten minutes of pretreatment with 25 mM miltefosine
reduced anti-IgE–induced histamine release by more than
50%. These findings were translated into a small study in
which the effect of miltefosine was tested on the allergic
response to a standard skin prick test. Five allergic patients
were treated on both arms with either placebo or a 6%
miltefosine solution. The inflammatory response was mea-
sured by the diameter of the resulting wheal and erythema.
Miltefosine was able to significantly reduce the inflammatory
response that resulted from injection with an allergen. A
control condition in which the patients were injected with
histamine showed no effect (Weller et al., 2009).
Miltefosine was also tested in a number of other mast
cell–related conditions. One such condition, mastocytosis, in-
volves the accumulation of mast cells in various organs, most
commonly in the skin. This rare condition affects mostly
children and skin manifestations cause symptoms related to
mast cell mediator release such as pruritus and flushing. A
topical 6% miltefosine solution and the glucocorticoid clobe-
tasol (0.5 mg/ml) were tested in a double-blind, placebo-
controlled trial with 39 adult patients for 2 weeks. Although it
seems that miltefosine may have reduced weal formation in
this study, none of the differences reached statistical signifi-
cance and it seems the study was underpowered to detect
a meaningful difference (Hartmann et al., 2010).
Chronic urticaria is a type of idiopathic rash that is relatively
common, affecting up to 1% of the population in the United
States. In most cases, the underlying cause is unclear but the
rash is the result of activated mast cells. Urticaria can be
treated with antihistamines; however, most patients with
chronic urticaria respond poorly and are often resistant.
Miltefosine was tested as an oral drug in a multicenter,
randomized, double-blind, placebo-controlled study that in-
cluded 54 patients with antihistamine-resistant chronic urti-
caria (Magerl et al., 2013). Patients took increasing dosages of
miltefosine (up to 150 mg/d unless intolerable adverse effects)
daily for 4 weeks. At the end of the treatment period,
miltefosine-treated patients showed substantial improvement,
as was clear from a specific urticaria activity score and a de-
crease in the number of wheals. Miltefosine treatment did not
reduce the intensity of pruritus.
Collectively, these data suggest that miltefosine could be
a potential drug for mast cell–related conditions.
Side Effects
Miltefosine has few side effects; however, the existing ef-
fects may hamper long-term use. From the phase II trials for
the oral use of miltefosine with cancer patients, it has be-
come clear that daily dosages of 150 mg and higher cause
potentially severe gastrointestinal side effects resulting in
loss of appetite, nausea, and vomiting (Verweij et al., 1992).
This can be solved by combining miltefosine treatment with
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antiemetics; however, the side effects are dose limiting in
some cases. Development of a better-tolerated formulation for
oncological indications was suspended due to the discovery of
perifosine, a better-tolerated oral anticancer drug (Crul et al.,
2002).
Miltefosine treatment may have teratogenic effects. Studies
on embryonic development and organogenesis of rats sug-
gested embryotoxic, fetotoxic, and teratogenic risks (Sindermann
and Engel, 2006). The same was reported from studies in
rabbits, although with the exception of the teratogenic effect.
Due to these findings, and because of a lack of human study
results, use of miltefosine during pregnancy is contraindi-
cated. This is especially a problem due to its long half-life. Six
months after treatment, miltefosine can still be measured in
serum and it is therefore advisable to use contraception for
6 months after stopping treatment.
In some patients, the renal function is affected and a rise in
creatinine levels is observed. In most cases, this effect is re-
versible. Studies in dogs showed no lasting effect of miltefo-
sine on the kidney (Bianciardi et al., 2009). Miltefosine might
have a direct effect on renal function, but a change in fluid
balance due to gastrointestinal effects might contribute.
Patients with Leishmaniasis who are treated with miltefosine
sometimes show elevated serum creatinine levels during
episodes of vomiting and dehydration (Sindermann and Engel,
2006), which supports this hypothesis.
In summary, a treatment schedule of 50–100 mg/d
miltefosine is generally well tolerated and rarely leads to
serious or treatment-limiting adverse effects. Studies on the
miltefosine treatment of visceral Leishmaniasis clearly in-
dicate that such a treatment schedule can be maintained
for at least 4 weeks. These data indicate that the potential
of miltefosine as a maintenance treatment of IBD could be
investigated.
Mechanism of Action
The precise mechanism of action of miltefosine is lacking
and may be different for different cell types. Because miltefosine
was originally selected as a cytostatic drug, most of the current
research is focused on explaining how miltefosine induces
apoptosis in cancer cells. Although the effect of miltefosine on
macrophages, lymphocytes, and mast cells appears to be dif-
ferent, it may involve similar pathways.
Miltefosine shows a resemblance to the membrane phos-
pholipid lysophosphatidylcholine. Its structural properties
allow miltefosine to integrate into the cellular membrane
(Rakotomanga et al., 2004). From there, it redistributes to the
endoplasmic reticulum as well as the Golgi and nuclear and
mitochondrial membranes. How this happens is unclear;
however, the process appears to be partly ATP-dependent in
Caco-2 colorectal cancer cells, suggesting active transport.
The normal membrane recycling process may be responsible
for the remainder of the intracellular transport of the drug
(Ménez et al., 2007). Because alkyl-phospholipids, such as
miltefosine, are more resistant to metabolizing enzymes, they
accumulate in the membranes and possibly affect the contin-
uous turnover of endogenous phospholipids.
Inhibition of phosphatidylcholine (PC) synthesis is believed
to be one of the most important effects of miltefosine incor-
poration into the cell membrane. PC is the most abundant
phospholipid in cellular membranes of eukaryotic cells and
interference with its production may predispose the cell to
undergo apoptosis (Wieder et al., 1998; van der Luit et al.,
2002). Miltefosine affects PC synthesis by inhibiting CTP:
phosphocholine cytidylyltransferase, the rate-limiting en-
zyme in the PC biosynthesis pathway at the endoplasmic
reticulum. This is supported by the fact that apoptosis can be
prevented by supplementing miltefosine-treated cells with
exogenous lysoPC, an alternative precursor for the synthesis
of PC. Because apoptosis induced by other triggers could
not be rescued by adding lysoPC, this is a strong suggestion
that inhibition of PC synthesis, indeed, is the mechanism of
miltefosine-induced apoptosis (Boggs et al., 1995; Baburina
and Jackowski, 1998; van der Luit et al., 2003).
In addition to inhibition of PC synthesis, miltefosine also
impairs signaling molecules through inhibition of phospholi-
pases. Phospholipases hydrolyze phospholipids and inhibition
results in a decrease in breakdown products, including the
important second messengers, diacylglycerol and phospha-
tidic acid. Further downstream, alkyl-phospholipids may im-
pact proliferation and cell survival through effects on protein
kinase B (Akt) (Song et al., 2005). Under normal conditions,
Akt can be activated once it is recruited and positioned at the
plasma membrane. Although this has not been described for
miltefosine, studies on perifosine suggest that treatment affects
the recruitment of Akt to the plasma membrane and displace-
ments of its ligands phosphatidylinositol-(3,4,5)-trisphosphate or
phosphatidylinositol-(3,4)-bisphosphate.
All of these effects could be caused by the disturbance of
membrane integrity and the functionality of lipid rafts
(Kondapaka et al., 2003). Miltefosine increases the membrane
fluidity inmacrophages (Ghosh et al., 2013), an effect that was
reported to decrease antigen presentation and stimulation
of T cells (Chakraborty et al., 2005). On the other hand,
miltefosine has an affinity for sterols and is known to stabilize
sterol-rich areas, such as lipid rafts, which increase antigen
presentation (Jiménez-López et al., 2010). Indeed, macro-
phages treated with miltefosine show an enhanced ability to
stimulate T cells, resulting in higher production of IL-2, IL-12,
TNF-a, and NO (Ghosh et al., 2013). The effect of miltefosine
on membrane integrity could also explain why mast cells are
inhibited in their IgE-dependent histamine release. Upon
activation, IgE receptors cluster in organized microdomains
(Weller et al., 2009; Silveira E Souza et al., 2011). Likewise,
T-cell activation is dependent on the formation and organiza-
tion of T-cell receptor microclusters and formation of the
immunologic synapse (Kabouridis and Jury, 2008). Signal-
ing molecules that are implicated as targets for miltefosine
treatment in cancer (e.g., Akt, Ras/Raf-1, and PLC) and second
messengers (e.g., phosphatidic acid and diacylglycerol) are also
important mediators in cells of the immune system. For ex-
ample, inhibition of even one of these molecules could explain
the inhibition of lymphocyte proliferation. Of course, future
investigations are needed to shed more light on this.
Conclusions
Miltefosine is an alkyl-phospholipid that was initially tried
unsuccessfully in several phase II trials in oncology and
hematology. This class of compounds was originally identified
for its stimulatory effect on macrophage phagocytosis and
several groups have observed that miltefosine may stimulate
myeloid cell–mediated immunity. At the same time, miltefosine
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shows profound inhibition of T-cell activation and miltefosine
was successfully applied in preclinical models of atopic
dermatitis and IBD. Given the well established and relatively
limited side effects and oral route of administration, miltefo-
sine may be a candidate for drug repurposing for immune-
mediated diseases that are in dire need for novel therapeutic
options such as IBD.
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